Technology

Anita Kawatra discusses advancing clinical and pharmaceutical progress while protecting patient privacy.

Accelerated implementation of AI platforms among pharma sales teams has highlighted the importance of the human factor.

What can both public and private sector stakeholders learn from current trends to accelerate innovation around the COVID-19 pandemic and other emerging global health threats, including antimicrobial resistance?

The next few years will require life science companies to bring consumer-facing digital services to the core of their corporate competence, rather than leaving it at the periphery of their business capabilities.

Computer-based simulations are a great approach to pharmaceutical sales training because they are engaging, realistic and help develop critical skills for a data-driven world, writes Jeremy Lovelace.

Wesam Badran looks at how the UK NHS can collaborate with pharma and med-tech partners to encourage digital innovation.

Grünenthal‘s Florent Edouard talks about AI‘s “key role in the future of marketing.”

Closing the gaps in complex therapy data remains a hurdle, but “getting clever” with AI can offer a path forward.

With AI/ML and cognitive technologies set to become a key enabler of the pharma commercialization process, Srini Rajamani outlines how pharma companies can leverage tech effectively.

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

How pharma firms assess their readiness for IDMP (Identification of Medicinal Products) is important for meeting compliance requirements and ensuring they are prepared for the digital product information management future, writes Adnan Jamil.

Emerging pharmaceutical technologies can aid in rapid drug and vaccine development — but only if pharma companies prioritize digitization initiatives.

How the UK is making progress in this hi-tech field.

Coordination of KOL engagement is all but impossible if the information an organization collects about them is fragmented. What is needed is a centralized database that captures all information about an expert from the multiple touch points across functions and geographies.

Developing a diversity mindset may begin at the top levels of the organization, but building diversity into the entire drug development life cycle ensures that it is an ongoing priority and a natural requirement of engaging with external stakeholders.

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Hannah Schofield and Lavan Thasarathakumar discuss what blockchain is, how it could help improve pharmaceutical supply chains, and the COVID-19 vaccine supply chain in particular, and touches on where we are already seeing blockchain technology being used in this area.

Amgen is collaborating on two digital health initiatives aimed at improving heart failure care and rehabilitation.

Exposing the truth behind AI myths highlighted by COVID.

Treating medical affairs solely as a support function is penny-wise and pound foolish. With the advent of machine learning, the medical affairs team can innovate and perform their many functions better and more efficiently.

In this roundtable discussion, Steve Gens, Remco Munnik and James Kelleher explore the potential and the practicalities of building future processes on a single, joined-up content platform.

New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.

A coalition of data, computational power, and AI is bringing the full potential of in silico medicine out of the realm of science fiction.

The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.

Merging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.